Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Lineage Cell Therapeutics (LCTX) Misses Q3 EPS by 6c
November 12, 2019 4:36 PM ESTLineage Cell Therapeutics (NYSE: LCTX) reported Q3 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $567 thousand versus the consensus estimate of $810 thousand.
New Data from Phase I/IIa Clinical Study of OpRegen® Presented at 2019 AAO Meeting; All Cohort 4 Patients Have Better Visual Acuity as of Last VisitImplemented Significant Additional Cost-Cutting Measures to Reduce Budget for 2020Received CE Mark Approval for Renevia®; Working to Identify European Commercial PartnerConducted Sales of 6.25 Million Shares of OncoCyte Corporation for $10.7 Million in Net ProceedsStrengthened... More